HPV Vaccine Dose

According to Global Cancer Observatory (GLOBOCAN) data, an estimated 663,301 women were diagnosed with cervical cancer worldwide in 2022, of which 348,874 women died from the disease

Besides MNCs, the top 30 list also includes two public-sector companies: Orissa Mining Corporation and HLL Life Care

The government has asked all states and Union Territories to create awareness on prevention of cervical cancer, the importance of HPV vaccine among girl and organise vaccination camps in schools. The Education and Health Ministry, in a joint letter, have informed states and UTs that the National Technical Advisory Group for Immunization (NTAGI) has recommended introduction of human papillomavirus (HPV) vaccine in the Universal Immunization Programme with a one-time catch-up for 9-14 year-old adolescent girls followed with routine introduction at nine years. "Globally, cervical cancer is the fourth most common cancer in women. In India, cervical cancer is the second most common cancer in women and India contributes the largest proportion of global cervical cancer burden. "Cervical cancer is a preventable and curable disease as long as it is detected early and managed effectively," said the letter written by Union Education Secretary Sanjay Kumar and Health Secretary Rajesh ...

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on COVID, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said. Exports will have to wait till 2024, its chief executive Adar Poonawalla told reporters here on Thursday evening, adding that the company has to build a scale of manufacturing to over 150 million for that. HPV vaccines prevent certain kinds of cervical cancer. SII is the world's largest vaccine manufacturer which rushed with the production of multiple COVID vaccines at its facilities located here once the shot was approved for use. "The HPV facility was used by the COVID vaccines during the pandemic. That's why we had to delay the larger launch to next year," Poonawalla said, speaking on the sidelines of an event. "We will be making a very small quantity and launching with the Indian government in the first quarter of next year. Followed by a capacity for 70

The locally developed Ceravac can play a critical role in the efficacy of the National Immunisation Mission

Serum India's product made in collaboration with state-run biotechnology department, expected to bring down prices

The inclusion of this vaccine in the NIM is a significant step in reducing cervical cancer burden among women

HPV infections are one of the leading causes of cervical cancer in women

The HPV vaccine, administered to pre-pubescent girls to prevent cervical cancer, has received considerable bad press over its 14 years

To protect against cervical cancer and other cancers caused by the human papillomavirus